Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: Evaluation of two diagnostic assays

Rheumatology (United Kingdom)

Volumn 52, Issue 3, 2013, Pages 501-509

  Vikerfors, Anna ^a   Johansson, Anna Britta ^b   Gustafsson, Johanna T ^a   Jönsen, Andreas ^c   Leonard, Dag ^d   Zickert, Agneta ^a   Nordmark, Gunnel ^d   Sturfelt, Gunnar ^c   Bengtsson, Anders ^c   Rönnblom, Lars ^d   Gunnarsson, Iva ^a   Elvin, Kerstin ^b   Svenungsson, Elisabet ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

2 glycoprotein I antibodies; Anticardiolipin antibodies; Cardiovascular disease; ELISA; Isotype; Lupus anticoagulant; Systemic lupus erythematosus; Thrombosis; Titre

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ANTIBODY DETECTION; ARTICLE; BRAIN ISCHEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TASK PERFORMANCE; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROIMMUNOASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; ODDS RATIO; SENSITIVITY AND SPECIFICITY;

EID: 84874048678     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes252     Document Type: Article

References (36)

1. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983;287:1088-9.
2. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
3. Galli M. Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome. Semin Thromb Hemost 2008;34: 329-34.
4. Villalta D, Alessio MG, Tampoia M et al. Accuracy of the first fully automated method for anti-cardiolipin and anti-beta2 glycoprotein I antibody detection for the diagnosis of antiphospholipid syndrome. Ann N Y Acad Sci 2009;1173:21-7.
5. Persijn L, Decavele AS, Schouwers S, Devreese K. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2011;128:565-9.
6. Tincani A, Andreoli L, Casu C, Cattaneo R, Meroni P. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus 2010;19: 432-5.
7. Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009;123: 482-7.
8. Pengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237-42.
9. Pengo V, Biasiolo A, Pegoraro C et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:1147-52.
10. Ruffatti A, Tonello M, Del Ross T et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006;96: 337-41.
11. Roubey RA. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus 2010;19:440-5.
12. Pengo V, Banzato A, Bison E et al. Antiphospholipid syndrome: critical analysis of the diagnostic path. Lupus 2010;19:428-31.
13. Turiel M, Sarzi-Puttini P, Peretti R et al. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke 2005;36:1490-4.
14. Stojanovich L, Markovic O, Marisavljevic D et al. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study. Lupus 2012;21:338-45.
15. Erkan D, Barbhaiya M, George D, Sammaritano L, Lockshin M. Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information? Lupus 2010;19:613-9.
16. Ruffatti A, Olivieri S, Tonello M et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008;6:1693-6.
17. Gustafsson J, Gunnarsson I, Borjesson O et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus-a prospective cohort study. Arthritis Res Ther 2009;11:R186.
18. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332-8.
19. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101:1827-32.
20. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011;270:110-22.
21. Escalante A, Brey RL, Mitchell BD Jr, Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995;98:559-65.
22. Cervera R, Khamashta MA, Shoenfeld Y et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009;68: 1428-32.
23. Fries JF, Holman HR. Systemic lupus erythematosus-a clinical analysis. In: Smith LH, ed. Major problems in internal medicine, Vol. VI. Philadelphia: WB Saunders, 1976.
24. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
25. Ho KT, Ahn CW, Alarcon GS et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology 2005;44:1303-7.
26. Svenungsson E, Gustafsson J, Leonard D et al. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010;69: 834-40.
27. Locht H, Wiik A. IgG and IgM isotypes of anti-cardiolipin and anti-beta2-glycoprotein i antibodies reflect different forms of recent thrombo-embolic events. Clin Rheumatol 2006;25:246-50.
28. Mehrani T, Petri M. IgM anti-beta2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. J Rheumatol 2011;38: 450-3.
29. Dropinski J, Szczeklik W, Rubis P, Sydor WJ. Antiphospholipid antibodies and carotid-artery intima-media thickness in young survivors of myocardial infarction. Med Sci Monit 2003;9:BR105-9.
30. Bili A, Moss AJ, Francis CW et al. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation 2000;102: 1258-63.
31. Lakos G, Kiss E, Regeczy N et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999;117:574-9.
32. Vaarala O, Manttari M, Manninen V et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91:23-7.
33. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010;19:419-23.
34. Gualtierotti R, Biggioggero M, Meroni PL. Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome. Clin Rev Allergy Immunol 2011, Mar 15 [epub ahead of print], doi: 10.1007/s12016-011-8268-9.
35. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986;41:8-15.
36. Lakos G, Favaloro EJ, Harris EN et al. International consensus guidelines on anticardiolipin and anti-beta(2) -glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012;64:1-10.